Safety and Efficacy of Long-term Treatment With Echinaforce® Over 4 Months
| Registry | NCT01021995 |
|---|---|
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional; randomized, parallel, masking: triple, prevention |
| Enrollment | 757 (Actual) |
| Sponsor | A. Vogel AG (Industry) |
| Conditions | Infections |
| Interventions | echinacea, placebo (Drug) |
| Dates | start 2009-10-01, primary completion 2010-08-01, completion 2011-04-01, first posted 2009-12-01, last updated 2014-07-23 |
| Locations | 1 site in United Kingdom |
Related Papers Related Patents Related Grants Related Experts
All trials for Infections All trials of echinacea All trials of placebo
Extracts produced from Echinacea purpurea are traditionally used for the prevention and the acute treatment of influenzal infections like the common cold. The aim of this clinical study is to assess clinical safety and efficacy of a treatment with Echinacea in comparison to placebo. 750 healthy subjects with a history of equal or more than 2 cold episodes per year will be recruited during October and November 2009 and will be treated with either Echinacea or placebo over a period of 4 months.
Throughout the study period adverse events (AEs) and adverse drug reactions (AEs with at least a possible causal relation to the treatment) will be recorded.
Common cold related symptoms will be recorded in a daily diary.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| echinacea | Experimental | Drug: echinacea | |
| placebo | Placebo comparator | Drug: placebo |
Sex: All, ages: 18 Years to any, accepts healthy volunteers
Inclusion Criteria: * On average more than 2 cold episodes per year * Age above 18 years * Good physical condition * Signed informed consent Exclusion Criteria: * Women without appropriate and effective contraception * Participation in a clinical trial 30 days prior to this trial * Pregnant or breast feeding women * Subjects with pre-existing cold symptoms for more than 24h at inclusion * Concurrent participation in another clinical trial * Intake of antimicrobial and/or antiviral medications at inclusion * Alcohol and/or drug abuse, narcotic drug addiction before and during trial (more than 50 gr and / or 10 cigarettes per day) * Psychiatric disorders which may influence the results of the trial, * epilepsy, suicide attempts * Planned surgical intervention during the trial. * Serious chronic diseases which influence the absorption, metabolism and the elimination of the investigational product, especially progressive systemic illnesses like tuberculosis, leukaemia, * collagen disorders and multiple sclerosis * Known AIDS, HIV-infections and autoimmune diseases * Known diabetes mellitus (type 1) * Corticosteroid-treated asthma * Atopic and allergic subjects (under medicinal treatment) * Known allergy to plants of the composite family (Asteraceae)
| Facility | City | Country | Status |
|---|---|---|---|
| Cardiff School of Biosciences | Cardiff, Wales | United Kingdom |